PDCD1 and gastric cancer: Based on these preliminary yet promising results, these anti-PD-1 antibodies (pembrolizumab, nivolumab, and avelumab) are now being investigated in various line settings of gastric cancer treatment either as a monotherapy or in combination with standard care chemotherapy with trial results available since 2017.